medRxiv preprint doi: https://doi.org/10.1101/2023.08.14.23289383; this version posted August 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

1

1	Alcohol use associated alterations in the circulating metabolite profile in the general
2	population and in individuals with major depressive disorder
3	
4	Olli Kärkkäinen ^{a,} *, Tommi Tolmunen ^{b,c} , Petri Kivimäki ^{b,d} , Karoliina Kurkinen ^b , Toni Ali-
5	Sisto ^b , Pekka Mäntyselkä ^{e,f} , Minna Valkonen-Korhonen ^{b,g} , Heli Koivumaa-Honkanen ^b , Kirsi
6	Honkalampi ^h , Anu Ruusunen ^{e,g,i} , Vidya Velagapudi ^j , Soili M. Lehto ^{k,l,m}
7	
8	^a School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
9 10	^b Institute of Clinical Medicine/Psychiatry, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
11 12	^c Department of Adolescent Psychiatry, Kuopio University Hospital, P.O. Box 100. 70029 KYS, Finland
13 14	^d City of Helsinki, Vuosaari Outpatient Psychiatry Clinic. Postal address: P.O. Box 6250, FI- 00099 City of Helsinki, Helsinki, Finland
15 16	^e Clinical Research and Trials Centre, Kuopio University Hospital, P.O. Box 100. 70029 KYS, Finland
17 18	^f Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland
19	^g Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland
20 21	^h School of Educational Sciences and Psychology, University of Eastern Finland, P.O. Box 111, 80101 Joensuu. Finland
22 23 24	ⁱ Deakin University, IMPACT - the Institute for Mental and Physical Health and Clinical Translation, Food & Mood Centre, IMPACT Strategic Research Centre, School of Medicine, P.O. Box 281, Geelong, VIC 3220, Australia
25	^j Metabolomics Unit, Institute for Molecular Medicine Finland FIMM, P.O. Box 20, FI-

26 00014 University of Helsinki, Finland NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 27 ^k Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- 28 ¹ R&D Department, Division of Mental Health Services, Akershus University Hospital,
- 29 Lørenskog, Norway
- ^m Psychiatry, University of Helsinki and Helsinki University Hospital, P.O. Box 20, FI-00014
- 31 Helsinki, Finland
- 32
- 33 * Correspondence: olli.karkkainen@uef.fi, School of Pharmacy, University of Eastern
- 34 Finland, P.O. Box 1627, 70211, Kuopio, Finland
- 35
- 36 Running title: Alcohol, metabolites, and depression
- 37
- 38 Keywords: Depression; Alcoholism; Metabolomics; Hippurate; 5-hydroxyindoleacetic acid

3

39 ABSTRACT

40	Our aim was to evaluate whether alcohol use is associated with changes in the circulating
41	metabolite profile similar to those present in persons with depression. If so, these findings
42	could partially explain the link between alcohol use and depression. We applied a targeted
43	liquid chromatography mass spectrometry method to evaluate correlates between
44	concentrations of 86 circulating metabolites and self-reported alcohol use in a cohort of the
45	non-depressed general population (GP) ($n = 247$) and a cohort of individuals with major
46	depressive disorder (MDD) ($n = 99$). Alcohol use was associated with alterations in
47	circulating concentrations of metabolites in both cohorts. Our main finding was that self-
48	reported alcohol use was negatively correlated with serum concentrations of hippuric acid in
49	the GP cohort. In the GP cohort, consumption of six or more doses per week was associated
50	with low hippuric acid concentrations, similar to those observed in the MDD cohort, but in
51	these individuals it was regardless of their level of alcohol use. Reduced serum
52	concentrations of hippuric acid suggest that already moderate alcohol use is associated with
53	depression-like changes in the serum levels of metabolites associated with gut microbiota and
54	liver function; this may be one possible molecular level link between alcohol use and
55	depression.

4

56 Introduction

Heavy alcohol use and lifetime occurrence of alcohol use disorder have been associated with 57 an increased incidence of a major depressive disorder (MDD) (Grant et al., 2015; McHugh & 58 Weiss, 2019; Odlaug et al., 2016). It has been estimated that around one in six of persons 59 with MDD is suffering from a current alcohol use disorder, and that around every third 60 61 person with MDD has had a lifetime occurrence of alcohol use disorder (DeVido & Weiss, 2012; Sullivan et al., 2005; Swendsen et al., 1998). However, the relationship between 62 moderate alcohol use and the incidence of MDD remains controversial: some studies show 63 possible small increase in the incidence of MDD (Odlaug et al., 2016), whereas others have 64 not been able to detect any associations (García-Esquinas et al., 2018) or even found evidence 65 for a reduced incidence of MDD (Bellos et al., 2016). Light alcohol use has not been 66 associated with an increased risk of MDD, and light drinkers are commonly used as controls 67 in these studies (Bellos et al., 2016; García-Esquinas et al., 2018; Grant et al., 2015; Odlaug 68 69 et al., 2016).

70

71 One possible mediating effect between alcohol use and MDD are changes in the activity of many metabolic processes. Heavy alcohol use has been associated with an altered 72 metabolome (for a review see Voutilainen and Kärkkäinen, 2019). For example, increased 73 74 levels of glutamate, citrate, alanine, phenylalanine, tyrosine, glucose, docosahexaenoate, 2piperidone and phosphatidylcholine diacyls, and decreased levels of glutamine, serotonin, 75 asparagine, hydroxysphingomyelins, gamma-aminobutyric acid (GABA) and 76 77 phosphatidylcholine acyl-alkyls have been associated with heavy alcohol use (Heikkinen et al., 2019; Jaremek et al., 2013; Kärkkäinen, Farokhnia, et al., 2021; Kärkkäinen, Kokla, et al., 78 2021; Lehikoinen et al., 2018; Würtz et al., 2016). In a prospective study with an over 30 79

5

80	years' follow-up, changes in the circulating metabolome, e.g., decreased levels of serotonin
81	and asparagine, preceded the diagnosis of diseases related to alcohol use (Kärkkäinen et al.,
82	2020). Similarly, also MDD has been associated with alterations in circulating levels of
83	metabolites – some of which have also been linked to alcohol use (e.g., glutamate,
84	phenylalanine, citrate and serotonin; for a review see Gadad et al., 2018). This evidence, in
85	addition to the observed overlap in the incidences of MDD and alcohol use, imply that there
86	may well be some shared underlying pathology related to the disturbances in metabolic
87	processes.
88	

We have now investigated whether alcohol use would be associated with similar changes in
the circulating metabolite profiles irrespective of the presence of depression by measuring the
associations between serum metabolite concentrations and self-reported alcohol use in two
cohorts: a non-depressed general population (GP) cohort and a cohort of individuals with
MDD.

6

94 Material and methods

95 Study cohorts

96 Two cohorts were used: 1) a general population cohort of non-depressed individuals (GP cohort), and 2) patients with major depressive disorder (MDD cohort) (Ali-Sisto et al., 2016; 97 Kraav et al., 2019). Both cohorts represented the same population, as Kuopio University 98 Hospital from where the MDD cohort was recruited serves the municipality area of 99 Lapinlahti from where the GP cohort was recruited. The Ethics Committee of Hospital 100 101 District of Northern Savo approved both studies. Participants provided written informed consent before entering the studies. 102 103 104 The non-depressed GP cohort was from a population-based follow-up study consisting of 480 individuals living in the municipality area of Lapinlahti, Finland in 2005. The sample 105 106 described here was collected as a part of a 5-year follow-up of the study in 2010 (n = 326) but only participants with alcohol use data (n = 289). Further exclusion criteria were a) Beck 107 Depression Inventory (BDI) score of ≥ 10 at the time of the study or 5 years earlier (Beck, 108 1961), or b) use of medication for depression. After exclusions, a total of 247 subjects were 109 included in the study (Table 1). 110

111

The MDD cohort consisted of 99 outpatients with MDD who were recruited from the
Department of Psychiatry of Kuopio University Hospital, Finland. The diagnosis of MDD
was confirmed with the structured clinical interview for DSM-IV (SCID) (DSM-IV;
American Psychiatric Association, 1994). The exclusion criteria were a) bipolar disorder, b)
psychotic disorders, c) a symptomology of mental illness due to alcohol or substance abuserelated diagnosis, d) epilepsy, and e) current somatic conditions preventing participation in

7

the study visits. Most of the participants in the MDD cohort were being administered some form of psychotropic medication: 81 had been prescribed with an antidepressant medication and 48 with an antipsychotic drug with some indication other than a psychotic disease (the medication use has been described in detail in Ali-Sisto, et al. 2016).

122

123 Alcohol use

124 The participants in both cohorts completed self-report questionnaires from which the weekly

alcohol use was extracted. Response alternatives were: < 1 drink/week, 1-2 drink(s)/week, 3-

126 5 drinks/week, 6-9 drinks/week, 10-14 drinks/week, 15-21 drinks/week, 22-28 drinks/week,

127 or > 28 drinks/week. One standard drink in Finland is defined as a drink containing 12 grams

128 of ethanol. Values higher than 21 drinks per week were considered heavy use, between 6 and

129 21 drinks per week moderate use, and below 6 drinks per week light drinking.

130

131 Background data, depressive symptoms and psychiatric medications

132 Background data was collected from the questionnaires completed by the participants.

133 Depressive symptoms were assessed with the Beck Depression Inventory (Beck, 1961) in

134 both cohorts. The use of prescription and over-the-counter medications was also recorded

135 with a questionnaire and confirmed from the prescription documents that the participants

136 provided. The following variables were also collected from both cohorts: age (in years),

137 gender (female/male), regular smoking (yes/no), cohabitation status (married or living with a

partner vs. living alone), and education level (higher education yes/no). Use of vegetables and

use of fruits (< 1 time/week, 1-5 times/week, > 5 times/week, according to Savolainen et al.

140 2014), and body mass index (BMI) were only available in the GP cohort.

8

141

142 Metabolite profiling analysis

Venous blood samples were obtained via venipuncture by trained laboratory personnel and 143 centrifuged to separate the serum. Before venipuncture, the participants were instructed to 144 fast for 12 hours. Serum samples were stored frozen at -80 °C until analyzed. The samples 145 were analyzed in the metabolomics unit of the Institute of Molecular Medicine Finland 146 147 (FIMM) in Helsinki, Finland. Metabolite profiling analysis of the samples was performed using liquid chromatography-mass spectrometry. Briefly, 10 µL of labeled internal standard 148 mixture was added to the 100 µL of samples, and the samples were allowed to equilibrate 149 with the internal standards. A total of 400 µL of extraction solvent (1% formic acid in 150 acetonitrile) was added and the collected supernatant was dispensed into an OstroTM 96-well 151 plate (Waters Corporation, Milford, USA) and then filtered by applying a vacuum at a delta 152 pressure of 300–400 mbar for 2.5 minutes on a Hamilton robot's vacuum station. After this, 5 153 µL of filtered sample extract was injected into an Acquity UPLC system coupled to a Xevo® 154 TQ-S triple quadrupole mass spectrometer (Waters Corporation, Milford, MA, USA), which 155 156 was operated in both positive and negative polarities with a polarity switching time of 20 msec for metabolite separation and quantification. The Multiple Reaction Monitoring (MRM) 157 158 acquisition mode was selected for the quantification of the metabolites. MassLynx 4.1 software was used for data acquisition, data handling, and instrument control. The data were 159 processed using TargetLynx software. 160

161

162 *Statistics*

163 In the comparison of the background characteristics of the cohorts, we used Mann-Whitney U 164 test for continuous and χ^2 test for binomial variables.

9

165

For the metabolite profiling data, only metabolites that were above the quantification limits in
at least 50% of subjects in at least one cohort were included in the study. Metabolite
concentrations below the quantification limit were excluded from the analysis, with the
exception of cotinine, where concentrations below the quantification limit were considered to
be zero.

171

172	In the statistical analysis of the metabolite data, the self-reported weekly alcohol drinking
173	levels were coded numerically $(1 = < 1 \text{ drink/week}, 2 = 1-2 \text{ drink(s)/week}, 3 = 3-5$
174	drinks/week, $4 = 6-9$ drinks/week, $5 = 10-14$ drinks/week, $6 = 15-21$ drinks/week, $7 = 22-28$
175	drinks/week, and $8 = > 28$ drinks/week) to allow us to conduct a regression analysis. We
176	analyzed the two cohorts separately for changes in the metabolite concentrations associated
177	with alcohol use. This was done to focus the analysis on alcohol use related changes, not to
178	changes associated with MDD, which have been reported earlier (Ali-Sisto et al. 2016). We
179	used linear regression to investigate correlations between self-reported weekly alcohol
180	drinking and serum metabolite concentrations. To account for multiple testing, we undertook
181	a principal component analysis and used the number of principal components needed to
182	explain 95% of variance in the datasets to adjust the α -level using Bonferroni's method to
183	0.001 (46 and 41 principal components were needed to explain 95% of variance in the GP
184	and MDD cohorts, respectively). Metabolites with p-values between 0.05 and 0.001 were
185	considered as trends.

For metabolites with a p-value below 0.05 in the initial analysis, we conducted a post-hocanalysis using linear regression with possible confounders previously associated with alcohol

- use and/or metabolite levels (age, sex, use of vegetables, use of fruits, smoking, BMI,
- education level, and cohabitation status) as covariates. We used JASP (version 0.14), SIMCA
- 191 (version 17, Umetrics), and Prism (GraphPad Software Inc., version 7) for statistical
- analyses, multivariate analysis, and figure preparation, respectively.

11

193 **Results**

The characteristics of the study participants in both cohorts are presented in Table 1. The GP cohort was older than the MDD cohort. With respect to the selection criteria, as would be expected, the MDD cohort had higher BDI scores when compared to the non-depressed GP cohort. Subjects in the MDD cohort were living alone and smoked regularly more often when compared to the GP cohort.

199

200 The correlations found between self-reported alcohol use and serum metabolite

201 concentrations with p-value below 0.05 in at least one cohort are shown in Figure 1.

However, at the multiple testing adjusted α level of 0.001, the only significant correlations

203 were observed between self-reported alcohol use and serum concentrations of hippuric acid

and chenodeoxycholic acid in the GP cohort, and xanthosine in the MDD cohort (Figure 1).

205 Correlations with p-values between 0.05 and 0.001 should be considered as trends that need
206 to be validated in larger cohorts. The correlations between self-reported alcohol use and all

207 86 measured metabolites are shown in the Supplementary Table 1.

208

A post-hoc analysis was conducted using linear regression with potential confounders. In the 209 GP cohort, most of the correlations between self-reported alcohol use and metabolite levels 210 remained significant after taking into account possible confounders (hippuric acid $\beta = -0.19$, 211 p = 0.0037; chenodeoxycholic acid $\beta = 0.19$, p = 0.0049; cytidine $\beta = 0.22$, p = 0.0011; 5-212 213 HIAA $\beta = -0.16$, p = 0.0183; taurocholic acid $\beta = 0.22$, p = 0.0012; glutamine $\beta = -0.20$, p = 0.0040; and serine $\beta = -0.16$, p = 0.0218). There were two exceptions; glycine ($\beta = -0.12$, p = 214 0.0785) and cotinine ($\beta = 0.03$, p = 0.5005). Instead of alcohol use, sex correlated more with 215 the glycine concentration ($\beta = -0.15$ and p = 0.0382) and smoking status more with cotinine 216

- 217 concentrations ($\beta = 0.74$, p < 0.0001). In the MDD cohort, all metabolites with a p-value
- below 0.05 in the initial analysis also had a p-value below 0.05 in the linear regression
- models when lifestyle factors were included as covariates (xanthosine $\beta = -0.38$, p = 0.0002;
- 220 GABA $\beta = 0.25$, p = 0.0186; cytidine $\beta = 0.21$, p = 0.0388; carnosine $\beta = -0.21$, p = 0.0348;
- and 2-aminoisobutyric acid $\beta = 0.22$, p = 0.0336).

13

222 Discussion

Our main finding was that in the GP cohort, at least moderately increased alcohol use was 223 associated with lower serum concentrations of hippuric acid. The hippuric acid 224 concentrations in those individuals who reported six or more alcohol doses per week were 225 similar to the concentrations observed in the MDD cohort regardless of their level of alcohol 226 227 use (Figure 1). These results are in line with previous reports, where decreased levels of hippuric acid have been associated with alcohol use, depression, anxiety disorders, and stress 228 (J. Chen et al., 2018; Kärkkäinen et al., 2020; Phua et al., 2015; P. Zheng, Wang, et al., 2013; 229 P. Zheng, Chen, et al., 2013). Although rather little is known to explain how hippuric acid 230 might influence behavior, previous studies have found that low hippuric acid levels may 231 impair neuronal development in fetal mouse brain (Ahmed et al., 2022; Vuong et al., 2020). 232 Moreover, in humans, low serum hippuric acid concentrations have been associated with mild 233 cognitive impairment, whereas high levels of hippuric acid have been linked with beneficial 234 effects on cognitive performance (Rutledge et al., 2021; Yilmaz et al., 2020). 235 236

237 In the GP cohort, similar trends were also seen in the association between self-reported alcohol use and concentrations of 5-HIAA and histidine. Interestingly, the composition of gut 238 microbiota may influence the serum levels of the following three compounds, i.e., hippuric 239 240 acid (Behr et al., 2017; Fujisaka et al., 2018; Lees et al., 2013; Pessa-Morikawa et al., 2022; Vuong et al., 2020; Williams et al., 2010), 5-HIAA (Lukić et al., 2019), and histidine (H. 241 Chen et al., 2019; Kawase et al., 2017). Moreover, both alcohol use and MDD have been 242 243 associated with an altered composition and changes in the function of the gut microbiota (Kelly et al., 2016; Leclercq et al., 2014; Llopis et al., 2016; Winter et al., 2018; P. Zheng et 244

14

al., 2016). Therefore, alterations in the gut microbiota could explain the correlations betweenserum levels of these metabolites, alcohol use and depression.

247

However, in the case of hippuric acid, the gut microbiota first makes benzoic acid from 248 phenolic compounds in the diet, and then the liver forms hippuric acid by combining benzoic 249 acid with glycine (Lees et al., 2013). The declines in serum hippuric acid concentrations 250 could therefore also be a reflection of disturbed liver function since decreased hippuric acid 251 252 production has been associated with alcohol use and impaired liver function (van Sumere et al., 1969). Furthermore, the intake of vegetables or fruits, the main sources of phenolic 253 compounds in the diet, did not significantly correlate with serum hippuric acid concentrations 254 255 in the present study. Therefore, differences in the intakes of food items with phenolic 256 compounds are not a likely explanation for the changes we observed in serum levels of hippuric acid. More research is needed to clarify the role of hippuric acid in alcohol use and 257 depression. 258

259

Moreover, we also observed a positive correlation between self-reported alcohol consumption 260 and serum concentrations of two bile acids, chenodeoxycholic acid and taurocholic acid. 261 These correlations could be associated with altered bile acid synthesis or metabolism, which 262 can also be linked with the gut microbiota (Bajaj, 2019). Increases in serum levels of bile 263 acids have been associated with the organ damage induced by alcohol consumption (Bajaj, 264 2019; Milstein et al., 1976; Trinchet et al., 1994). Interestingly, there was no correlation 265 between self-reported alcohol use and chenodeoxycholic acid levels in the MDD cohort, 266 which could be associated with altered cholesterol metabolism in MDD since cholesterol is a 267 starting precursor for bile acid formation (Kraav et al., 2019; Lehto et al., 2010). Moreover, 268

15

in the MDD cohort, we observed a negative correlation between xanthosine and self-reported
alcohol use, which was not observed in the GP cohort. This difference is likely linked to the
previously reported dysregulation of purine metabolism in the same cohort (Ali-Sisto et al.,
2016).

273

Furthermore, there were several metabolites, which were positively (cytidine, taurocholic 274 acid) or negatively (glycine, serine and glutamine) correlated with self-reported alcohol use 275 in both the GP and MDD cohorts with similar standardized β coefficients (Figure 1). 276 However, due to the smaller sample size, these correlations were not statistically significant 277 in the MDD cohort. These alterations are in line with results from previous studies 278 279 investigating changes associated with alcohol use in the human circulating metabolome 280 (Kärkkäinen et al., 2020; Lehikoinen et al., 2018; Voutilainen & Kärkkäinen, 2019; Würtz et al., 2016). 281

282

Limitations of the study include the relatively small number of subjects in the MDD cohort. 283 Based on the present results, moderate alcohol use seems to be associated with small-to-284 medium effect size changes in the serum metabolite profile and therefore future studies 285 should examine larger cohorts. We estimated that a sample size of 315 would be needed to 286 observe small-to-medium effect size ($f^2 > 0.1$) correlations between alcohol use and 287 metabolite concentrations with the corrected α level used in the present study (0.0001) with 288 0.95 statistical power. Furthermore, future studies should also use other biomarkers such as 289 phosphatidylethanols, to assess recent alcohol use instead of relying solely on self-reporting 290 (Y. Zheng et al., 2011). 291

- 293 The present results show that already moderate alcohol use is associated with depression-like
- changes in the serum levels of a metabolite, hippuric acid, which has been linked with both
- the gut microbiota and liver function. This indicates that changes in the metabolites
- associated with the gut microbiota and liver function could be one of the molecular level
- 297 links between alcohol use and depression, although further research will be needed to verify
- this hypothesis.

299 Funding source

- 300 This work was supported by The Finnish Foundation for Alcohol Studies (OK), and the
- 301 Finnish Medical Foundation (SML).

302

303 Declaration of competing interest

304 OK is a co-founder of Afekta Technologies Ltd., company providing metabolomics analysis

services (not used in the present study). All other authors have no conflicts of interest to

306 declare.

307

308 Acknowledgements

309 The authors wish to thank Dr. Jorma Savolainen for his significant contribution in the

310 collection of the Lapinlahti Study sample, and Dr. Ewen MacDonald for proofreading.

311

312 Data availability statement

313 The data that support the findings of this study are available on request from the

314 corresponding author, OK. The data are not publicly available due to their containing

- information that could compromise the privacy of research participants. The study plan
- 316 approved by the ethical committee and the participant consent terms preclude public sharing
- 317 of these sensitive data, even in anonymized form.

18

318 **References**

- Ahmed, H., Leyrolle, Q., Koistinen, V., Kärkkäinen, O., Layé, S., Delzenne, N., & Hanhineva, K. (2022).
- 320 Microbiota-derived metabolites as drivers of gut-brain communication. *Gut Microbes*, 14(1),
- 321 2102878. https://doi.org/10.1080/19490976.2022.2102878
- Ali-Sisto, T., Tolmunen, T., Toffol, E., Viinamäki, H., Mäntyselkä, P., Valkonen-Korhonen, M.,
- 323 Honkalampi, K., Ruusunen, A., Velagapudi, V., & Lehto, S. M. (2016). Purine metabolism is
- 324 dysregulated in patients with major depressive disorder. *Psychoneuroendocrinology*, 70, 25–
- 325 32. https://doi.org/10.1016/j.psyneuen.2016.04.017
- Bajaj, J. S. (2019). Alcohol, liver disease and the gut microbiota. *Nature Reviews. Gastroenterology* &
- 327 *Hepatology*, *16*(4), 235–246. https://doi.org/10.1038/s41575-018-0099-1
- Beck, A. T. (1961). An Inventory for Measuring Depression. *Archives of General Psychiatry*, 4(6), 561.

329 https://doi.org/10.1001/archpsyc.1961.01710120031004

- Behr, C., Kamp, H., Fabian, E., Krennrich, G., Mellert, W., Peter, E., Strauss, V., Walk, T., Rietjens, I. M.
- 331 C. M., & van Ravenzwaay, B. (2017). Gut microbiome-related metabolic changes in plasma of 332 antibiotic-treated rats. *Archives of Toxicology*, *91*(10), 3439–3454.
- 333 https://doi.org/10.1007/s00204-017-1949-2
- Bellos, S., Skapinakis, P., Rai, D., Zitko, P., Araya, R., Lewis, G., Lionis, C., & Mavreas, V. (2016).
- 335 Longitudinal association between different levels of alcohol consumption and a new onset of
- 336 depression and generalized anxiety disorder: Results from an international study in primary

337 care. *Psychiatry Research*, 243, 30–34. https://doi.org/10.1016/j.psychres.2016.05.049

- 338 Chen, H., Nwe, P.-K., Yang, Y., Rosen, C. E., Bielecka, A. A., Kuchroo, M., Cline, G. W., Kruse, A. C.,
- 339 Ring, A. M., Crawford, J. M., & Palm, N. W. (2019). A Forward Chemical Genetic Screen
- 340 Reveals Gut Microbiota Metabolites That Modulate Host Physiology. Cell, 177(5), 1217-
- 341 1231.e18. https://doi.org/10.1016/j.cell.2019.03.036

19

- 342 Chen, J., Bai, S.-J., Li, W., Zhou, C., Zheng, P., Fang, L., Wang, H., Liu, Y., & Xie, P. (2018). Urinary
- biomarker panel for diagnosing patients with depression and anxiety disorders. *Translational Psychiatry*, 8(1), 192. https://doi.org/10.1038/s41398-018-0245-0
- 345 DeVido, J. J., & Weiss, R. D. (2012). Treatment of the depressed alcoholic patient. *Current Psychiatry*
- 346 *Reports*, 14(6), 610–618. https://doi.org/10.1007/s11920-012-0314-7
- Fujisaka, S., Avila-Pacheco, J., Soto, M., Kostic, A., Dreyfuss, J. M., Pan, H., Ussar, S., Altindis, E., Li, N.,
- 348 Bry, L., Clish, C. B., & Kahn, C. R. (2018). Diet, Genetics, and the Gut Microbiome Drive
- 349 Dynamic Changes in Plasma Metabolites. *Cell Reports*, 22(11), 3072–3086.
- 350 https://doi.org/10.1016/j.celrep.2018.02.060
- Gadad, B. S., Jha, M. K., Czysz, A., Furman, J. L., Mayes, T. L., Emslie, M. P., & Trivedi, M. H. (2018).
- 352 Peripheral biomarkers of major depression and antidepressant treatment response: Current
- knowledge and future outlooks. *Journal of Affective Disorders*, 233, 3–14.
- 354 https://doi.org/10.1016/j.jad.2017.07.001
- 355 García-Esquinas, E., Ortolá, R., Galán, I., Soler-Vila, H., Laclaustra, M., & Rodríguez-Artalejo, F. (2018).
- 356 Moderate alcohol drinking is not associated with risk of depression in older adults. *Scientific*

357 Reports, 8(1), 11512. https://doi.org/10.1038/s41598-018-29985-4

- 358 Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J.,
- 359 Smith, S. M., Huang, B., & Hasin, D. S. (2015). Epidemiology of DSM-5 Alcohol Use Disorder:
- 360 Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA
- 361 *Psychiatry*, 72(8), 757. https://doi.org/10.1001/jamapsychiatry.2015.0584
- Heikkinen, N., Kärkkäinen, O., Laukkanen, E., Kekkonen, V., Kaarre, O., Kivimäki, P., Könönen, M.,
- 363 Velagapudi, V., Nandania, J., Lehto, S. M., Niskanen, E., Vanninen, R., & Tolmunen, T. (2019).
- 364 Changes in the serum metabolite profile correlate with decreased brain gray matter volume
- in moderate-to-heavy drinking young adults. *Alcohol*, *75*, 89–97.
- 366 https://doi.org/10.1016/j.alcohol.2018.05.010

20

367	Jaremek, M., Yu, Z.	, Mangino, M., Mittelstrass,	K., Prehn, C., Singmann	, P., Xu, T., Dahmen, N.,
-----	---------------------	------------------------------	-------------------------	---------------------------

- 368 Weinberger, K. M., Suhre, K., Peters, A., Döring, A., Hauner, H., Adamski, J., Illig, T., Spector,
- 369 T. D., & Wang-Sattler, R. (2013). Alcohol-induced metabolomic differences in humans.
- 370 Translational Psychiatry, 3(7), e276–e276. https://doi.org/10.1038/tp.2013.55
- 371 Kärkkäinen, O., Farokhnia, M., Klåvus, A., Auriola, S., Lehtonen, M., Deschaine, S. L., Piacentino, D.,
- 372 Abshire, K. M., Jackson, S. N., & Leggio, L. (2021). Effect of intravenous ghrelin
- administration, combined with alcohol, on circulating metabolome in heavy drinking
- individuals with alcohol use disorder. *Alcoholism, Clinical and Experimental Research*, 45(11),
- 375 Article 11. https://doi.org/10.1111/acer.14719
- 376 Kärkkäinen, O., Klåvus, A., Voutilainen, A., Virtanen, J., Lehtonen, M., Auriola, S., Kauhanen, J., &
- 377 Rysä, J. (2020). Changes in circulating metabolome precede alcohol-related diseases in
- 378 middle-aged men: A prospective population-based study with a 30-year follow-up.
- 379 Alcoholism: Clinical and Experimental Research, 44, 2457–2467.
- 380 https://doi.org/10.1111/acer.14485
- 381 Kärkkäinen, O., Kokla, M., Lehtonen, M., Auriola, S., Martiskainen, M., Tiihonen, J., Karhunen, P. J.,
- 382 Hanhineva, K., & Kok, E. (2021). Changes in the metabolic profile of human male
- 383 postmortem frontal cortex and cerebrospinal fluid samples associated with heavy alcohol

384 use. Addiction Biology, e13035. https://doi.org/10.1111/adb.13035

- Kawase, T., Nagasawa, M., Ikeda, H., Yasuo, S., Koga, Y., & Furuse, M. (2017). Gut microbiota of mice
 putatively modifies amino acid metabolism in the host brain. *British Journal of Nutrition*,
- 387 *117*(6), 775–783. https://doi.org/10.1017/S0007114517000678
- 388 Kelly, J. R., Borre, Y., O' Brien, C., Patterson, E., El Aidy, S., Deane, J., Kennedy, P. J., Beers, S., Scott,
- 389 K., Moloney, G., Hoban, A. E., Scott, L., Fitzgerald, P., Ross, P., Stanton, C., Clarke, G., Cryan,
- 390 J. F., & Dinan, T. G. (2016). Transferring the blues: Depression-associated gut microbiota
- induces neurobehavioural changes in the rat. *Journal of Psychiatric Research*, 82, 109–118.
- 392 https://doi.org/10.1016/j.jpsychires.2016.07.019

393 Kraav, S.-L., Tolmunen, T., Kärkkäinen, O., Ruusunen, A., Viinamäki, H., Mäntyselkä, P., Koivumaa-

- 394 Honkanen, H., Valkonen-Korhonen, M., Honkalampi, K., Herzig, K.-H., & Lehto, S. M. (2019).
- 395 Decreased serum total cholesterol is associated with a history of childhood physical violence
- in depressed outpatients. *Psychiatry Research*, 272, 326–333.
- 397 https://doi.org/10.1016/j.psychres.2018.12.108
- Leclercq, S., Matamoros, S., Cani, P. D., Neyrinck, A. M., Jamar, F., Stärkel, P., Windey, K., Tremaroli,
- 399 V., Bäckhed, F., Verbeke, K., de Timary, P., & Delzenne, N. M. (2014). Intestinal permeability,
- 400 gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. *Proceedings*
- 401 of the National Academy of Sciences, 111(42), E4485–E4493.
- 402 https://doi.org/10.1073/pnas.1415174111
- Lees, H. J., Swann, J. R., Wilson, I. D., Nicholson, J. K., & Holmes, E. (2013). Hippurate: The Natural
- 404 History of a Mammalian–Microbial Cometabolite. Journal of Proteome Research, 12(4),
- 405 1527–1546. https://doi.org/10.1021/pr300900b
- Lehikoinen, A. I., Kärkkäinen, O. K., Lehtonen, M. A. S., Auriola, S. O. K., Hanhineva, K. J., & Heinonen,
- 407 S. T. (2018). Alcohol and substance use are associated with altered metabolome in the first
- 408 trimester serum samples of pregnant mothers. *European Journal of Obstetrics & Gynecology*
- 409 *and Reproductive Biology*, 223, 79–84. https://doi.org/10.1016/j.ejogrb.2018.02.004
- 410 Lehto, S. M., Niskanen, L., Tolmunen, T., Hintikka, J., Viinamäki, H., Heiskanen, T., Honkalampi, K.,
- 411 Kokkonen, M., & Koivumaa-Honkanen, H. (2010). Low serum HDL-cholesterol levels are
- 412 associated with long symptom duration in patients with major depressive disorder: HDL-C
- 413 and the duration of depression. *Psychiatry and Clinical Neurosciences*, 64(3), 279–283.
- 414 https://doi.org/10.1111/j.1440-1819.2010.02079.x
- Llopis, M., Cassard, A. M., Wrzosek, L., Boschat, L., Bruneau, A., Ferrere, G., Puchois, V., Martin, J. C.,
- 416 Lepage, P., Le Roy, T., Lefèvre, L., Langelier, B., Cailleux, F., González-Castro, A. M., Rabot, S.,
- 417 Gaudin, F., Agostini, H., Prévot, S., Berrebi, D., ... Perlemuter, G. (2016). Intestinal microbiota

418 contributes to individual susceptibility to alcoholic liver disease. *Gut*, *65*(5), 830–839.

419 https://doi.org/10.1136/gutjnl-2015-310585

- 420 Lukić, I., Getselter, D., Koren, O., & Elliott, E. (2019). Role of Tryptophan in Microbiota-Induced
- 421 Depressive-Like Behavior: Evidence From Tryptophan Depletion Study. Frontiers in
- 422 Behavioral Neuroscience, 13, 123. https://doi.org/10.3389/fnbeh.2019.00123
- 423 McHugh, R. K., & Weiss, R. D. (2019). Alcohol Use Disorder and Depressive Disorders. Alcohol
- 424 *Research : Current Reviews, 40*(1), arcr.v40.1.01. https://doi.org/10.35946/arcr.v40.1.01
- 425 Milstein, H. J., Bloomer, J. R., & Klatskin, G. (1976). Serum bile acids in alcoholic liver disease.
- 426 Comparison with histological features of the disease. *The American Journal of Digestive*

427 *Diseases*, 21(4), 281–285. https://doi.org/10.1007/BF01071839

- 428 Odlaug, B. L., Gual, A., DeCourcy, J., Perry, R., Pike, J., Heron, L., & Rehm, J. (2016). Alcohol
- 429 Dependence, Co-occurring Conditions and Attributable Burden. *Alcohol and Alcoholism*,
- 430 51(2), 201–209. https://doi.org/10.1093/alcalc/agv088
- 431 Pessa-Morikawa, T., Husso, A., Kärkkäinen, O., Koistinen, V., Hanhineva, K., livanainen, A., & Niku, M.
- 432 (2022). Maternal microbiota-derived metabolic profile in fetal murine intestine, brain and
- 433 placenta. *BMC Microbiology*, 22(1), 46. https://doi.org/10.1186/s12866-022-02457-6
- 434 Phua, L. C., Wilder-Smith, C. H., Tan, Y. M., Gopalakrishnan, T., Wong, R. K., Li, X., Kan, M. E., Lu, J.,
- 435 Keshavarzian, A., & Chan, E. C. Y. (2015). Gastrointestinal Symptoms and Altered Intestinal
- 436 Permeability Induced by Combat Training Are Associated with Distinct Metabotypic Changes.
- 437 *Journal of Proteome Research*, 14(11), 4734–4742.
- 438 https://doi.org/10.1021/acs.jproteome.5b00603
- 439 Rutledge, G. A., Sandhu, A. K., Miller, M. G., Edirisinghe, I., Burton-Freeman, B. B., & Shukitt-Hale, B.
- 440 (2021). Blueberry phenolics are associated with cognitive enhancement in supplemented
- 441 healthy older adults. *Food & Function*, *12*(1), 107–118. https://doi.org/10.1039/d0fo02125c

- 442 Sullivan, L. E., Fiellin, D. A., & O'Connor, P. G. (2005). The prevalence and impact of alcohol problems
- 443 in major depression: A systematic review. The American Journal of Medicine, 118(4), 330-

444 341. https://doi.org/10.1016/j.amjmed.2005.01.007

- 445 Swendsen, J. D., Merikangas, K. R., Canino, G. J., Kessler, R. C., Rubio-Stipec, M., & Angst, J. (1998).
- 446 The comorbidity of alcoholism with anxiety and depressive disorders in four geographic
- 447 communities. Comprehensive Psychiatry, 39(4), 176–184. https://doi.org/10.1016/s0010-

448 440x(98)90058-x

Trinchet, J. C., Gerhardt, M. F., Balkau, B., Munz, C., & Poupon, R. E. (1994). Serum bile acids and

450 cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features.

451 *Journal of Hepatology*, *21*(2), 235–240. https://doi.org/10.1016/s0168-8278(05)80401-5

- 452 van Sumere, C. F., Teuchy, H., Pé, H., Verbeke, R., & Bekaert, J. (1969). Quantitative investigation on
- 453 the hippuric acid formation in healthy and diseased individuals. *Clinica Chimica Acta*, *26*(1),
 454 85–88. https://doi.org/10.1016/0009-8981(69)90289-7
- 455 Voutilainen, T., & Kärkkäinen, O. (2019). Changes in the Human Metabolome Associated With

456 Alcohol Use: A Review. *Alcohol and Alcoholism*, *54*(3), 225–234.

- 457 https://doi.org/10.1093/alcalc/agz030
- 458 Vuong, H. E., Pronovost, G. N., Williams, D. W., Coley, E. J. L., Siegler, E. L., Qiu, A., Kazantsev, M.,
- 459 Wilson, C. J., Rendon, T., & Hsiao, E. Y. (2020). The maternal microbiome modulates fetal
- 460 neurodevelopment in mice. *Nature*, *586*(7828), 281–286. https://doi.org/10.1038/s41586-
- 461 020-2745-3
- 462 Williams, H. R., Cox, I. J., Walker, D. G., Cobbold, J. F., Taylor-Robinson, S. D., Marshall, S. E., &
- 463 Orchard, T. R. (2010). Differences in gut microbial metabolism are responsible for reduced
- 464 hippurate synthesis in Crohn's disease. *BMC Gastroenterology*, *10*(1), 108.
- 465 https://doi.org/10.1186/1471-230X-10-108

24

466 Winter, G., Hart, R. A., Charlesworth, R. P. G., & Sharpley, C. F. (2018). Gut microbiome and

- 467 depression: What we know and what we need to know. *Reviews in the Neurosciences, 29*(6),
- 468 629–643. https://doi.org/10.1515/revneuro-2017-0072
- 469 Würtz, P., Cook, S., Wang, Q., Tiainen, M., Tynkkynen, T., Kangas, A. J., Soininen, P., Laitinen, J.,
- 470 Viikari, J., Kähönen, M., Lehtimäki, T., Perola, M., Blankenberg, S., Zeller, T., Männistö, S.,
- 471 Salomaa, V., Järvelin, M.-R., Raitakari, O. T., Ala-Korpela, M., & Leon, D. A. (2016). Metabolic
- 472 profiling of alcohol consumption in 9778 young adults. *International Journal of*
- 473 Epidemiology, 45(5), 1493–1506. https://doi.org/10.1093/ije/dyw175
- 474 Yilmaz, A., Ugur, Z., Bisgin, H., Akyol, S., Bahado-Singh, R., Wilson, G., Imam, K., Maddens, M. E., &
- 475 Graham, S. F. (2020). Targeted Metabolic Profiling of Urine Highlights a Potential Biomarker
- 476 Panel for the Diagnosis of Alzheimer's Disease and Mild Cognitive Impairment: A Pilot Study.
- 477 *Metabolites, 10*(9), E357. https://doi.org/10.3390/metabo10090357
- 478 Zheng, P., Chen, J., Huang, T., Wang, M., Wang, Y., Dong, M., Huang, Y., Zhou, L., & Xie, P. (2013). A
- 479 Novel Urinary Metabolite Signature for Diagnosing Major Depressive Disorder. *Journal of*

480 Proteome Research, 12(12), 5904–5911. https://doi.org/10.1021/pr400939q

- Zheng, P., Wang, Y., Chen, L., Yang, D., Meng, H., Zhou, D., Zhong, J., Lei, Y., Melgiri, N. D., & Xie, P.
- 482 (2013). Identification and validation of urinary metabolite biomarkers for major depressive
- 483 disorder. *Molecular & Cellular Proteomics: MCP*, *12*(1), 207–214.
- 484 https://doi.org/10.1074/mcp.M112.021816
- Zheng, P., Zeng, B., Zhou, C., Liu, M., Fang, Z., Xu, X., Zeng, L., Chen, J., Fan, S., Du, X., Zhang, X., Yang,
- 486 D., Yang, Y., Meng, H., Li, W., Melgiri, N. D., Licinio, J., Wei, H., & Xie, P. (2016). Gut
- 487 microbiome remodeling induces depressive-like behaviors through a pathway mediated by
- 488 the host's metabolism. *Molecular Psychiatry*, 21(6), 786–796.
- 489 https://doi.org/10.1038/mp.2016.44
- 490 Zheng, Y., Beck, O., & Helander, A. (2011). Method development for routine liquid chromatography-
- 491 mass spectrometry measurement of the alcohol biomarker phosphatidylethanol (PEth) in

- 492 blood. Clinica Chimica Acta, 412(15-16), 1428-1435.
- https://doi.org/10.1016/j.cca.2011.04.022 493

26

495 Table 1: Background characteristics of the study cohorts.

	Cohort			
Variable	GP(n = 247)	MDD (n=99)	test value	p-value
Age (years, mean ±SD)	54.6 (±9.5)	39.4 (±11.9)	4213 ^b	< 0.0001
Gender (% females)	118 (48 %)	56 (56%)	2 ^a	0.1393
Living with a partner (n, %)	206 (83%)	52 (53%)	37 ^a	< 0.0001
BDI score (mean ±SD)	3 (±2)	28 (±12)	22733 ^b	< 0.0001
Self-reported alcohol use (n, %)			13 ^a	0.0742
Light alcohol use	192 (78%)	77 (78%)		
< 1 doses/week	75 (30%)	34 (34%)		
1-2 doses/week	59 (24%)	26 (26%)		
3-5 doses/week	58 (23%)	17 (17%)		
Moderate alcohol use	54 (22%)	19 (19%)		
6-9 doses/week	26 (10%)	15 (15%)		
10-14 doses/week	23 (9%)	2 (2%)		
15-21 doses/week	5 (2%)	2 (2%)		
Heavy alcohol use	1 (0.4%)	3 (3%)		
22-28 doses/week	1 (0.4%)	2 (2%)		
>28 doses/week	0 (0%)	1 (2%)		
Smoking (n, %)	48 (19%)	33 (33%)	18 ^a	< 0.0001
Antidepressant use (n, %)	0 (0%)	84 (85%)	277 ^a	< 0.0001
BMI (mean ±SD)	28 (±5)	-		
Use of vegetables (n, %)				
>5 times/week	81 (32%)	-		
1-5 times/week	85 (34%)	-		
<1 times/week	86 (34%)	-		
Use of fruits (n, %)				
>5 times/week	95 (38%)	-		
1-5 times/week	88 (35%)	-		
<1 times/week	69 (27%)	-		

496

Legend: GP, general population cohort; MDD, cohort of patients with a major depressive 497 disorder; BDI, Beck Depression Inventory; BMI, body mass index; SD, standard deviation; 498 significant difference between the study cohorts as evaluated by: $a = \chi 2$ test, or b = Mann-1499

Whitney U test. 500

27



